ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2756

Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

Marc C. Hochberg1, John Carrino 2, Thomas Schnitzer 3, Ali Guermazi 4, David Walsh 5, Alexander White 6, Satoru Nakajo 7, Robert Fountaine 8, Anne Hickman 8, Glenn Pixton 9, Lars Viktrup 10, Mark T. Brown 8, Christine R. West 8 and Kenneth M. Verburg 8, 1University of Maryland School of Medicine, Baltimore, MD, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Boston Medical Center, Boston, 5Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, 6Progressive Medical Research, Port Orange, FL, 7Nakajo Orthopaedic Clinic, Miyagi, Japan, 8Pfizer Inc, Groton, CT, 9Pfizer Inc, Morrisville, NC, 10Eli Lilly and Company, Indianapolis, IN

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Osteoarthritis, safety and growth factors, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T090: Osteoarthritis – Clinical II: Novel Therapies (2756–2761)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies, intravenous tanezumab was effective and generally well tolerated, and the risk of increased joint damage required further assessment. This study was conducted to evaluate the efficacy and safety of subcutaneous (SC) tanezumab vs NSAID in patients (pts) with OA; findings on the long-term risk of joint safety events are presented here.

Methods: Eligible pts had OA of the hip or knee based on ACR criteria with x-ray confirmation; baseline (BL) WOMAC Pain and Physical Function scores of ≥5 (11-pt numeric rating scale [0-10]); BL Patient’s Global Assessment of OA (PGA-OA) of “fair,” “poor,” or “very poor”; history of inadequate pain relief with acetaminophen; inadequate pain relief with/intolerance to tramadol or an opioid; or unwillingness to take an opioid. Pts were on a stable dose of oral NSAID before study entry and during screening. Pts were randomized to tanezumab (2.5 mg or 5 mg SC q 8 wk) or NSAID (naproxen 500 mg, celecoxib 100 mg, or diclofenac ER 75 mg orally bid) for 56 wk. Radiographic/magnetic resonance imaging was performed at screening, wk 24 and 56 (treatment period), and wk 80 (safety period). Pts meeting pre-specified criteria for increased severe or persistent joint pain had additional follow-up imaging. All images were evaluated by central reader; joint safety events and total joint replacements (TJR) were adjudicated by blinded committee. Observation time-adjusted rates/1,000 pt-y of adjudicated rapidly progressive OA type 1 or 2 (RPOA1 or 2), primary osteonecrosis, subchondral insufficiency fracture (SIF), and pathologic fracture over 80 wk were analyzed (combined as primary composite joint safety endpoint and individually), as was the TJR rate.

Results: A total of 2,996 pts were randomized, received ≥1 dose of study drug, and were analyzed for joint safety events. During 80 wk of observation, the time-adjusted rate/1,000 pt-y for the primary composite joint safety endpoint was higher with tanezumab 2.5 mg (37.4 [p=0.002]) and tanezumab 5 mg (71.5 [p< 0.001]) than NSAID (14.8) (Table). The majority of joint safety events adjudicated as RPOA were RPOA1 (89 of 107 [83.2%]). Rates of RPOA1 were higher with tanezumab 2.5 mg (28.4 [p=0.005]) and tanezumab 5 mg (49.1 [p< 0.001]) than NSAID (10.9), as were rates of RPOA2 (2.9 [p=0.321] and 13.9 [p=0.001] vs 1.0, respectively). In the tanezumab 2.5 and 5 mg groups, SIF rates were 5.8 (p=0.539) and 6.9 (p=0.364) vs 3.9 in the NSAID group. Primary osteonecrosis occurred in 1 pt in the tanezumab 5-mg group; no pathological fractures were observed. TJR rates were also higher with tanezumab 2.5 mg (51.8 [p=0.003]) and 5 mg (79.7 [p< 0.001]) than NSAID (25.7). Of 159 pts with TJR, 28 (17.6%) had an adjudicated joint safety outcome; in these 28 pts, the event was RPOA1 in 42.9%; RPOA2, 39.3%; primary osteonecrosis, 3.6%; and SIF, 14.3%.

Conclusion: In this study, adjudicated joint safety endpoints, particularly RPOA1, and TJR were significantly more common with tanezumab than NSAID. Additional research is ongoing to explore potential reasons for this imbalance and dose-response relationships.

Table. Summary of adjudicated joint safety events and TJR with tanezumab compared with NSAID in pts with OA over 80 wk of observation -56-wk treatment and 24-wk safety period-.


Disclosure: M. Hochberg, Bioiberica SA, 5, Bone Therapeutics, 5, BriOri Biotech, 4, Bristol Myers Squibb, 5, Eli Lilly, 5, Elsevier, 7, EMD Serono, 5, EMD Serono Research and Development Institute, Inc., 5, Galapagos, 5, Galapagos, IQVIA and Hoffman LaRoche, 9, IBSA Biotechniq SA, 5, Novartis Pharma AG, 5, Pfizer, 5, Pfizer Inc, 5, Plexxikon, 5, Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba, 5, Rheumcon, Inc, 3, Samumed LLC, 5, Theralogix LLC, 4, 5, TissueGene Inc, 5, UpToDateTM, 7; J. Carrino, Covera Health, 5, Image Analysis Group, 5, Image Biopsy Lab, 5, Pfizer, 5, Simplify Medical, 5; T. Schnitzer, AbbVie, 2, Aptinyx, Astellas, Calibr, Eli Lilly and Company, 2, 5, Flexion, 2, Galapagos, 2, GlaxoSmithKline, Grunenthal, 2, Kolon TissueGene, 2, Pfizer, 2, 5, Regeneron, 2, Sanofi, Vertex; A. Guermazi, AstraZeneca, 5, BICL, 1, Boston Imaging Core Lab (BICL), 1, Galapagos, 5, MerckSerono, 5, Pfizer, 5, Roche, 5, Shareholder BICL,LLC, 1, TissueGene, 5; D. Walsh, GlaxoSmithKline, 5, Pfizer Ltd, 5, 8, Sherwood Forest Hospitals NHS Foundation Trust (non-personal pecuniary), 2; A. White, None; S. Nakajo, None; R. Fountaine, Pfizer, 1, 3, 4; A. Hickman, Pfizer, 1, 3, 4; G. Pixton, Pfizer, 1, 3, 4; L. Viktrup, Eli Lilly and Company, 1, 3, 4; M. Brown, Pfizer, 1, 3, 4; C. West, Pfizer, 1, 3, 4; K. Verburg, Pfizer, 1, 3, 4.

To cite this abstract in AMA style:

Hochberg M, Carrino J, Schnitzer T, Guermazi A, Walsh D, White A, Nakajo S, Fountaine R, Hickman A, Pixton G, Viktrup L, Brown M, West C, Verburg K. Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/subcutaneous-tanezumab-versus-nsaid-for-the-treatment-of-osteoarthritis-joint-safety-events-in-a-randomized-double-blind-active-controlled-80-week-phase-3-study/. Accessed February 1, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-tanezumab-versus-nsaid-for-the-treatment-of-osteoarthritis-joint-safety-events-in-a-randomized-double-blind-active-controlled-80-week-phase-3-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences